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T2* Magnetic Resonance: Iron and Gold†
Dudley J. Pennell, MD, FRCP, FACC, FESC
London, United KingdomAs a clinician, it is important to never underesti-
mate the power of basic science to deliver new
answers to old questions. At the outset of the
development of magnetic resonance (MR), scien-
tists demonstrated differences in magnetic relax-
ation between normal and malignant tissues that
were of significant interest, although only clinically
exploited later through MR spectroscopy. Some 30
years on, the fundamental magnetic properties of
tissues are once again becoming more interesting in
a range of diseases. The most relevant relaxation
parameter is T2* (pronounced T2 star), which has
the valuable property of being shortened in tissues
containing particulate iron, which disturbs the local
magnetic microenvironment. Although T1 and T2
See page 572
are also shortened by particulate iron, the relaxation
effects are less marked. T2* is not significantly
affected by elemental iron in solution, such as
nontransferrin-bound iron. Conditions in which
this T2* is relevant include reversible neurological
dysfunction in Freidreich’s ataxia (1), hemorrhage
into atherosclerotic plaque (2), hemorrhage into
myocardium during infarction (3), and myocardial
siderosis. In these conditions, the abnormal distri-
bution of iron is a measurement and treatment
target. Most importantly, currently T2* can be used
to investigate a wide range of conditions of abnor-
†Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
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and 2206 trials).mal cardiac iron deposition, including the obliga-
tory transfusion-dependent hemoglobinopathies
such as beta-thalassemia major, the less frequently
transfusion-dependent sickle cell disease, and rarer
hematological conditions that cause myocardial sid-
erosis such as sideroblastic anemia and Blackfan-
Diamond syndrome. Thalassemia patients are the
most common group, and the best studied. These
patients are typically transfused 2 U of blood/
month, which leads to a 5 to 6 g iron load/year,
which humans (unlike some animals) are unable to
excrete. The iron is therefore deposited throughout
the body and is compartmentalized intracellularly in
siderosomes as iron particles.
These conditions (and others) may cause cardiac
siderosis, but only in the long term, as the liver
usually stores the overwhelming majority of excess
iron. The reasons for the development of cardiac
iron loading in only some patients are not yet fully
clear, but probably relate to chronic chelator usage
with loading and unloading kinetics that vary be-
tween tissues, and genetic factors. Cardiac siderosis
manifests itself as a toxic cardiomyopathy, which is
the cause of death in 50% to 70% of beta-
thalassemia major patients. The onset of cardiomy-
opathy is insidious, and unfortunately, the diagnosis
is usually masked by left ventricular ejection frac-
tions (EF), which are in the normal range for
nonanemic people. Measurement by cardiovascular
magnetic resonance (CMR) in thalassemia patients,
in whom cardiac siderosis has been excluded by
demonstration of normal myocardial T2* values,
has shown that thalassemia patients run a high EF
and cardiac output at rest (4), which is attributable
to the chronic anemia as thalassemia patients are
typically maintained with a pre-transfusion hemo-
globin in the region of 10 g/dl, which suppresses
extramedullary hematopoiesis but minimizes the
iron-loading transfusions. The unexpected conse-
quence of this is that asymptomatic left ventricular
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580ysfunction may be advanced before being recog-
ized. The clinical course of progression to decom-
ensated heart failure may be catastrophic, with
atients entering a vicious cycle of rapidly deterio-
ating cardiac function that is assumed to be the
esult of massive release of toxic elemental iron
reaking intracellular havoc, and sometimes myo-
arditis. The trigger f o r decompensation often
ppears to be relatively trivial, including infec-
ion. Historical records suggest that quite recent
ohorts of patients had up to a 50% death rate
efore age 35. Thus relative to patients dying
rom heart failure due to coronary disease in their
id-70s, we could state that such patients are
osing up to 40 years of life by comparison. The
ragedy of this situation is that aggressive iron
helation treatments can reverse early and even
dvanced myocardial siderosis (5 ). Therefore,
hat has been urgently needed is a means to
dentify myocardial siderosis as a much earlier
tage and to do so reliably.
The assessment of myocardial iron using T2*
as first proposed in 1991, and has proved useful
ecause of its simplicity (6 ). Myocardial T2* is
asy to measure using gradient echo imaging,
hich is commonly used for CMR, and can be
erformed in a single breath-hold of about 10 s
 7 ). Analysis is equally fast and can be completed
n 1 min. Interstudy reproducibility is excellent at
% (8 ), and roll-out across the world has proved
uccessful (9,10). Calibration of iron levels
gainst T2* has been shown in animals and is
waited in humans (11). The normal myocardial
2* is 40 ms and has a nonparametric distribu-
ion such that normal subjects do not have values
elow 20 ms. Therefore, iron overload in the
eart is “defined” as a T2*  20 ms, and there is
 clear relation between T2* values below 20 ms
nd falling EF (2 ). In patients presenting in heart
ailure, 89% have a myocardial T2*  10 ms (12).
herefore, myocardial T2* values  10 ms are
onsidered severe and an indication for increased
ron chelation.
Since the introduction of this new gold standard
or evaluating myocardial siderosis, there has been
onsiderable interest in comparing T2* with more
onventional measurement techniques to assess
hether something more widely available, such as
cho, might be useful as an alternative. The paper
y Leonardi et al. (13) in this issue of iJACC
JACC: Cardiovascular Imaging) assessed the role of
cho diastolic function measurement in patients
ith thalassemia (13). There are obvious reasons 6or examining this because diastolic dysfunction
s considered an early marker of left ventricular
mpairment and is potentially more sensitive than
F. Leonardi et al. (13) found that all patients
ad a restrictive filling pattern and normal relax-
tion. There was no significant correlation be-
ween EF and E/E= or the Tei index, and only
eak correlations were found with E/A and E= .
here was no significant correlation between
yocardial T2* and any of the diastolic parame-
ers measured. The work of Leonardi et al. (13)
ccords with and builds on previous data exam-
ning diastolic function in thalassemia. West-
ood et al. (14) showed disappointingly weak
elations between cardiac T2* and CMR mea-
ures of diastolic dysfunction (14), and Vogel et
l. (15) found that tissue Doppler imaging
howed more abnormalities in cardiac siderosis
sing parameters reflecting systolic contraction
han diastolic relaxation.
Therefore, these data suggest that echo-based
iastolic parameters should not be used to assess
yocardial iron loading. The T2* CMR remains
he gold standard for assessing myocardial siderosis
nd needs to be made available to all patients with
halassemia. This is a challenging, but not impos-
ible, task. Validated centers now stretch from
alifornia eastward through the Mediterranean,
iddle East, South Asia, Far East, and Australia.
roduct CMR sequences are available for 1.5-T
canners from Siemens (Erlangen, Germany), GE
ealthcare (Milwaukee, Wisconsin), and Philips
ealthcare (Best, the Netherlands), and European
nion/U.S. Food and Drug Administration–
pproved T2* analysis software (CMRtools, Car-
iovascular Imaging Solutions, London, United
ingdom) is available. Once early myocardial sid-
rosis is identified, randomized controlled trials
ndicate that deferiprone is superior for myocardial
ron removal in comparison with standard treat-
ent with deferoxamine (16,17), and deferiprone
se is linked with improved survival (18,19). De-
eriprone is available worldwide, and although it is
ot currently licensed in the U.S., it is available
ithin a compassionate use program. Additional
andomized controlled data on cardiac efficacy using
he new iron chelator deferasirox compared with
eferoxamine are awaited with considerable inter-
st, and these should be available in 2011.
eprint requests and correspondence: Dr. Dudley J. Pen-
ell, Professor of Cardiology, Cardiovascular MR Unit,
oyal Brompton Hospital, Sydney Street, London SW3
NP, United Kingdom. E-mail: d.pennell@ic.ac.uk.
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